Bioheart, Inc. is a biotechnology company specializing in the development and commercialization of regenerative cell therapies for cardiovascular and musculoskeletal diseases. Founded in 1997 and headquartered in Fort Lauderdale, Florida, Bioheart focuses on harnessing the body’s own healing mechanisms through autologous cell processing systems. The company’s core mission is to improve patient outcomes by providing minimally invasive treatments that target damaged tissues and promote natural repair.
Bioheart’s flagship product, MyoCell®, is an injectable autologous skeletal myoblast therapy designed to treat patients with advanced congestive heart failure. The therapy involves harvesting the patient’s own muscle cells, expanding them in a closed, sterile system, and reintroducing them into damaged heart tissue to stimulate regeneration. In addition to cardiac applications, Bioheart has developed orthopedic cell therapies aimed at managing joint pain and promoting cartilage repair in degenerative conditions.
The company’s proprietary cell processing platform, the ASC-ME® System, supports both clinical research and commercial manufacturing by automating cell isolation and expansion under stringent quality controls. Bioheart collaborates with leading medical centers and academic institutions across the United States and Europe to conduct clinical trials, refine its protocols, and accelerate regulatory approvals. These partnerships enable the company to advance its pipeline while generating real-world evidence to support broader adoption of regenerative therapies.
Under the leadership of CEO John Winslow and Chairman Tom Textor, Bioheart has pursued a history of innovation in regenerative medicine and secured several patent families covering its cell processing technologies. The executive team combines deep expertise in biotechnology, clinical development, and commercialization to guide the company’s strategic growth. With a focus on scalable manufacturing and targeted therapeutic indications, Bioheart continues to position itself at the forefront of the emerging regenerative medicine market.
AI Generated. May Contain Errors.
Free USRM Stock Alerts